Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
clinical trials
life sciences
migraine
4
×
national blog main
eli lilly
indiana blog main
indiana top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco blog main
san francisco top stories
teva pharmaceutical
amgen
bausch health
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
calcitonin gene-related peptide
detroit blog main
detroit top stories
dihydroergotamine
drugs
fda
fremanezumab
glaxosmithkline
impel neuropharma
medical device
multiple myeloma
national
national top stories
san diego blog main
san diego top stories
satsuma pharmaceuticals
seattle blog main
seattle top stories
texas blog main
What
drug
4
×
approval
companies
migraine
new
class
fda
won
activity
announced
approved
arguments
big
bio
biogen’s
biopharmaceutical
biotech
commercialized
competitors
convo
days
decades
decision
developed
dog
drugs
earlier
eli
failures
firm
hasn’t
headache
ipo
ipos
late
leading
lilly
line
littered
make
Language
unset
Current search:
migraine
×
drug
×
@xconomy.com
4 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines